Collegium Pharmaceutical Inc (COLL)

Return on equity (ROE)

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Net income (ttm)	US$ in thousands	48,155	9,016	-11,161	-29,359	-25,002	-42,837	-35,248	42,786	71,517	103,509	106,749	41,964	26,752	17,593	198	-12,572	-22,722	-11,435	-21,828	-30,176
Total stockholders’ equity	US$ in thousands	195,431	178,873	200,805	179,733	194,842	197,194	197,612	196,076	202,928	251,094	253,066	170,035	186,031	172,686	155,767	141,063	87,432	84,258	85,823	86,350
ROE		24.64%	5.04%	-5.56%	-16.33%	-12.83%	-21.72%	-17.84%	21.82%	35.24%	41.22%	42.18%	24.68%	14.38%	10.19%	0.13%	-8.91%	-25.99%	-13.57%	-25.43%	-34.95%

December 31, 2023 calculation

ROE = Net income (ttm) ÷ Total stockholders’ equity
= $48,155K ÷ $195,431K
= 24.64%

Over the past eight quarters, Collegium Pharmaceutical Inc's return on equity (ROE) has fluctuated significantly. In Q4 2023, the ROE stood at 24.64%, marking a substantial increase compared to the previous quarters. Prior to this, there was a notable improvement in Q3 2023 with an ROE of 5.04%, following two quarters of negative ROE figures in Q2 2023 (-5.56%) and Q1 2023 (-16.33%).

Looking further back, the ROE in Q4 2022 was -12.83%, which continued a trend of negative ROE observed throughout the year, with the lowest point recorded in Q2 2022 at -21.72%. The only positive ROE figure during this period was in Q1 2022 at 21.82%.

The fluctuating ROE trend indicates that Collegium Pharmaceutical Inc's profitability and efficiency in generating returns from shareholders' equity have been inconsistent. Further analysis and investigation into the factors driving these fluctuations are necessary to understand the underlying performance drivers and potential areas for improvement within the company.